A detailed history of Group One Trading, L.P. transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 1,691 shares of DNLI stock, worth $41,294. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,691
Holding current value
$41,294
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$20.96 - $31.05 $35,443 - $52,505
1,691 New
1,691 $49,000
Q1 2024

May 10, 2024

BUY
$15.83 - $23.35 $133,842 - $197,424
8,455 New
8,455 $173,000
Q1 2023

May 12, 2023

BUY
$21.91 - $32.67 $1.09 Million - $1.63 Million
49,760 New
49,760 $1.15 Million
Q2 2022

Aug 11, 2022

SELL
$20.88 - $35.19 $71,764 - $120,948
-3,437 Reduced 49.39%
3,522 $104,000
Q1 2022

May 12, 2022

SELL
$29.0 - $47.27 $214,194 - $349,136
-7,386 Reduced 51.49%
6,959 $224,000
Q4 2021

Feb 11, 2022

BUY
$42.59 - $55.02 $610,953 - $789,261
14,345 New
14,345 $640,000
Q3 2021

Nov 12, 2021

SELL
$48.48 - $78.23 $57,836 - $93,328
-1,193 Closed
0 $0
Q2 2021

Aug 10, 2021

BUY
$50.3 - $78.44 $60,007 - $93,578
1,193 New
1,193 $94,000
Q2 2020

Aug 13, 2020

SELL
$16.01 - $28.82 $92,153 - $165,887
-5,756 Closed
0 $0
Q1 2020

May 13, 2020

BUY
$14.2 - $27.98 $81,735 - $161,052
5,756 New
5,756 $101,000
Q4 2019

Feb 10, 2020

SELL
$14.4 - $19.99 $31,680 - $43,978
-2,200 Closed
0 $0
Q3 2019

Nov 12, 2019

BUY
$15.32 - $21.92 $33,704 - $48,224
2,200 New
2,200 $34,000
Q1 2019

May 13, 2019

SELL
$17.99 - $24.65 $1,798 - $2,465
-100 Closed
0 $0
Q4 2018

Feb 06, 2019

BUY
$13.88 - $21.75 $1,388 - $2,175
100 New
100 $2,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.28B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.